PERSPECTIVE article
Front. Pediatr.
Sec. Pediatric Oncology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1611187
Bridging the Gap: Cancer Scientific Equity, Global Child Health, and Distribution of CAR T-Cell Therapy Clinical Trials in Childhood Cancer
Provisionally accepted
Kevin Fernando Montoya-Quintero1
Johana Galván-Barrios2Darly Martinez-Guevara3Diana Dueñas3John Montenegro3
Yamil Liscano3*- 1University of Caldas, Manizales, Caldas, Colombia
- 2Costa University Corporation, Barranquilla, Atlantico, Colombia
- 3University of Santiago de Cali, Cali, Colombia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment land-scape for childhood cancer. However, its global distribution remains unequal, with limited access in regions bearing a high burden of disease. This situation raises critical concerns about scientific equity in pediatric oncology research worldwide. To date, no study has systematically examined the scientific coherence between child health needs, global health indicators, and the frequency of CAR T-cell therapy clinical trials for childhood cancer. This omission represents a significant gap in the literature, with im-plications for global health equity and cancer research prioritization. A mixed-method analysis was conducted using global health metrics, child cancer indicators, and data from the Global Observatory on Health Research and Development. A total of 414 CAR T-cell therapy clinical trial participations across 30 countries were identified, with a heavy concentration in China (n=161) and the United States (n=84). High-income countries represented 73.3% of those participating. Multiple linear regression identified only one significant predictor for clinical trials participation: youth mortality (<15 years) (Coef. = 161.53; p = 0.045). The Lasso model revealed key predictors such as deaths due to alcohol use (Coef. = 29.99) and obesity (Coef. = 9.62) in children aged 5-14. Findings reveal a structural misalignment between childhood cancer disease burden and research activity in advanced therapies. Clinical trials are concentrated in countries with stronger scientific infrastructure rather than those with the greatest health needs, reinforcing cancer scientific inequities in the production and distribution of biomedical knowledge.
Keywords: Neoplasms, Antineoplastic Agents, clinical trials, global health, Child, Evidence gaps
Received: 13 Apr 2025; Accepted: 23 Jun 2025.
Copyright: © 2025 Montoya-Quintero, Galván-Barrios, Martinez-Guevara, Dueñas, Montenegro and Liscano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yamil Liscano, University of Santiago de Cali, Cali, Colombia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.